CBT-161 is an ADC that STI-A0602, the monoclonal antibody targeting c-Met, links tubulin inhibitors or DNA damaging agents via C-lock. Preclinical study showed that CBT-161 significantly inhibited tumor growth.
Structure of
* For research and manufacturing use only. We do not sell to patients.
Size | Price | Stock | Quantity |
---|---|---|---|
-- | $-- | In stock |
Looking for different specifications? Click to request a custom quote!
Capabilities & Facilities
CBT-161 is an innovative antibody-drug conjugate (ADC) that represents a significant advancement in targeted cancer therapy. Primarily, it leverages STI-A0602, a monoclonal antibody that precisely targets the c-Met receptor—a critical component often overexpressed in various malignancies. By linking STI-A0602 to cytotoxic agents, such as tubulin inhibitors or DNA damaging agents, through a proprietary C-lock technology, CBT-161 ensures enhanced delivery of these cytotoxic compounds directly to the cancer cells. The underlying mechanism of CBT-161 allows for precise targeting and subsequent destruction of cancer cells while largely sparing normal, healthy cells. Preclinical studies have shown that CBT-161 effectively inhibits tumor growth by leveraging its dual-action approach of targeting and destroying malignant cells.
Targeted Cancer Therapy: The primary application of CBT-161 is in the domain of targeted cancer therapy. Monoclonal antibodies, like STI-A0602, are designed to recognize specific proteins or receptors on the surface of cancer cells. Once the antibody part of CBT-161 binds to the c-Met receptor on cancer cells, it facilitates the direct delivery of the conjugated cytotoxic drug to these targeted cells. This ensures a high concentration of the therapeutic agent at the tumor site, enhancing efficacy while minimizing systemic exposure and subsequent side effects. This targeted delivery mechanism forms the backbone of precision oncology, offering hope for improved outcomes in cancers where c-Met plays a pivotal role, such as gastric, kidney, and certain types of lung cancers.
Combination Therapy Potential: In contemporary oncology, combination therapies offer a strategic advantage by attacking cancer through multiple fronts. CBT-161, with its highly specific targeting mechanism, presents an opportunity to be part of such combination treatment regimens. By combining CBT-161 with other therapeutic agents, especially those targeting different pathways or having complementary mechanisms, clinicians can potentially increase the therapeutic window and efficacy while minimizing side effects. Additionally, CBT-161’s ability to target c-Met enhances its suitability for combination with other inhibitors like checkpoint inhibitors, further amplifying the anticancer response while enabling a multifaceted attack on cancer’s hallmarks. This combinatorial approach not only improves outcomes but also pushes forward the envelope of therapeutic possibilities in cancer care.
Contact our experts today for pricing and comprehensive details on our ADC offerings.
From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.
Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.
Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.